Mitochondria-targeted neutral and cationic iridium(iii) anticancer complexes chelating simple hybrid sp²-N/sp³-N donor ligands

Abstract

Most platinum group-based cyclometalated neutral and cationic anticancer complexes with the general formula [(C˄N)2Ir(XY)]0/+ (neutral complex: XY = bidentate anionic ligand; cationic complex: XY = bidentate neutral ligand) are notable...

Iridium(iii) complexes conjugated with naproxen exhibit potent anti-tumor activities by inducing mitochondrial damage, modulating inflammation, and enhancing immunity

“…Firstly, iridium complexes can target organelles such as mitochondria, lysosomes, and endoplasmic reticulum by regulating their lipophilicity. 3–10 Secondly, due to the strong spin–orbit coupling effect and rich photophysical and chemical properties of cyclometalated iridium( iii ) complexes, they exhibit photodynamic and photothermal activity. 11–17 In addition, iridium complexes can induce multiple modes of cell death, including apoptosis, 18,19 autophagy, 20 oncosis, 21 ferroptosis, 22 pyroptosis, 23 etc .…”